Recommended genotyping for KRAS, NRAS, BRAF V600E, and MSI (not including ERBB2 amplification and NTRK fusion as these were not recommended for CRC in professional guidelines and not tested on tissue at the time of patient enrollment) was completed by tissue testing in 57.4% (89/155) of patients, RAS and BRAF V600E testing was completed in 60.6% (94/155), and RAS testing alone was completed in 94.2% (146/155). This evidence concerns the gene ERBB2 and colorectal carcinoma.